Additionally, Cancer Genetics noted that last week it sold off its clinical laboratory business to siParadigm, a specialty reference laboratory, for about $1 million.
The test could potentially enable labs to bring resistance testing in house, rather than send testing out to Canada's National Microbiology Laboratory.
The test measures levels of seven autoantibodies to tumor-associated antigens and is designed to detect all forms of lung cancer at any stage.
The iC-GN Assay detects target DNA and identifies gram-negative organisms associated with gram-negative bacteremia, and three antibiotic-resistance markers.
Nestlé Health said that employees of Prometheus are becoming employees of Precision IBD, with the exception of those working in its point-of-care diagnostic business.
Quest has made a strategic investment of an undisclosed amount in Sharecare, and Sharecare has named Quest its preferred laboratory partner.
The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.
Within the "Big Three" conditions, misdiagnoses related to stroke, sepsis, and lung cancer accounted for the most high-severity diagnostic error cases.
The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.